Epigenetics Market Size Drives at 15.32% CAGR to Reach USD 70.51 Billion by 2034

The global epigenetics market size is calculated at USD 19.55 billion in 2025 and is expected to reach around USD 70.51 billion by 2034, growing at a CAGR of 15.32% for the forecasted period.

Ottawa, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The global epigenetics market size was valued at USD 16.95 billion in 2024 and is predicted to hit around USD 70.51 billion by 2034, rising at a 15.32% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

The global epigenetics market is driven by its expanding healthcare applications, growing innovations, and disease burden.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5164

Key Takeaways

North America held a major revenue of 39% share of the market in 2023.
Asia Pacific is expected to witness the fastest growth with a CAGR of 17.73% in the epigenetics market during the forecast period.
By product, the reagents segment held the major revenue share of 34% in the market in 2023.
By product, the services segment is expected to grow at a CAGR of 17.70% during the forecast period.
By technology, the DNA methylation segment held a 46% share in the market in 2023.
By technology, the histone acetylation segment is expected to grow at a notable CAGR of 18.19% during the forecast period.
By application, the oncology segment held a 70% share in the market in 2023
By application, the non-oncology segment is expected to grow at a CAGR of 16.32% during the forecast period.
By end-use, the academic research segment held a 39% share in the epigenetics market in 2023.
By end-use, the clinical research segment is expected to show the fastest growth with a CAGR of 16.40% during the forecast period.

Market Overview & Potential

The epigenetic market encompasses the study of the changes in gene expression without altering the DNA sequence. They are responsible for modifying the DNA or histone proteins with mechanisms such as DNA methylation, histone methylation, large non-coding RNA, etc. This, in turn, is increasing their use to discover the disease mechanism, identify the biomarkers, conduct genetic studies, and for drug development. Moreover, their applications in oncology, cardiovascular diseases, inflammatory diseases, neurological diseases, etc is are driving the market growth.

What are the Major Growth Drivers Epigenetics Market?

The growing demand for personalized medicine is the major driver, increasing the use of epigenetics. Its growing innovations to improve its detection and sequencing accuracy are also contributing to the market growth. Other drives include growing diseases, applications, and outsourcing trends.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Drifts in the Epigenetics Market?

The market has been expanding due to the growing funding and R&D to launch and enhance the epigenetics applications.

In September 2025, a Series B round of financing of $60 million was announced to be completed by Epigenic Therapeutics. The development of EPI-001 and EPI-003 for the treatment of hypercholesterolemia and chronic hepatitis B, respectively, will be supported by this funding.
In June 2025, a total of $16.6M in funding was received by Zenith Epigenetics. Zenith Epigenetics is a well-known developer of small-molecule BET inhibitors for autoimmune disorders and cancer.
In May 2025, a total of $130 million was secured by NewLimit, which is a longevity biotech company in the Series B funding round. The mission of the company to extend the human healthspan with epigenetic reprogramming will be supported by this funding.
In February 2025, the TruDiscovery Grant, providing $400,000 in funding to organizations and researchers focusing on advancing longevity science, diagnostic innovation, and DNA methylation, was launched by TruDiagnostic, which is the leader in epigenetic testing and research.

What is the Significant Challenge in the Epigenetics Market?

Lack of skilled personnel and high cost act as a major challenge in market growth. This can lead to incorrect interpretation of the epigenetic data and reduce the adoption rates of the epigenetic technologies. Moreover, regulatory barriers and a lack of standardization are other challenges in the market.

Regional Analysis

Why did North America Dominate the Epigenetics Market in 2023?

North America captured the biggest revenue share of the epigenetics market in 2024. The presence of the advanced healthcare sector and growing healthcare investments, increased the use of epigenetics. The growing R&D has enhanced their innovations. This increased their adoption rates and enhanced the market growth.

What Made the Asia Pacific the Fastest Growing Region in the Epigenetics Market in 2023?

The Asia Pacific is estimated to be the fastest-growing region in the epigenetics market during the upcoming years. The expanding healthcare sector is increasing the adoption of epigenetics and driving its research activities. The growing disease burden and awareness are also increasing its use. Thus, these factors, along with government support, are promoting the market growth.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By product analysis

Why Did the Reagents Segment Dominate in the Epigenetics Market in 2023?

By product, the reagents segment held the largest share of 34% in the market in 2023, due to their repeated use. They were essential for epigenetic techniques. At the same time, the growing research and development has also increased their demand. Thus, this enhanced the market growth.

By product, the services segment is expected to show lucrative growth with a CAGR of 17.70% during the predicted time. The growing outsourcing trends are increasing the use of the services. Moreover, the rising demand for personalized medication is also increasing its use. Similarly, growing advancements are also contributing to the same.

By technology analysis

Which Technology Type Segment Held the Dominating Share of the Epigenetics Market in 2023?

By technology, the DNA methylation segment held the dominating share 46% in the market in 2023, due to its increased use. They were also used due to their wide range of applications. They were widely used for biomarker diagnostics, especially in oncology. They were also used in the development of precision medicine.

By technology, the histone acetylation segment is expected to grow at a significant rate with a CAGR of 18.19% during the predicted time. Their use in gene regulation is increasing. This, in turn, is increasing their use in the development of therapeutic approaches for cancer and neurological diseases.

By application analysis

What Made Oncology the Dominant Segment in the Epigenetics Market in 2023?

By application, the oncology segment led the market with a 70% share in 2023, due to the use of epigenetics for its detection. They were also used for the development of precision medicine and the treatment monitoring. Moreover, the R&D for the development of targeted treatment options with the use of epigenetics also increased.

By application, the non-oncology segment is expected to show lucrative growth with a CAGR of 16.32% during the upcoming years. The use of epigenetics is increasing for developing new treatment options for non-oncology diseases such as cardiovascular and metabolic diseases. Their growing incidences are also contributing to their increased demand.

By end-user analysis

How the Academic Research Segment Dominated the Epigenetics Market in 2023?

By end-use, the academic research segment dominated the market with a 39% share in 2023, driven by growth in the R&D. These researchers are focusing on understanding the epigenetic mechanism and enhancing its applications. Moreover, the government grants are boosting the research activities.

By end-use, the clinical research segment is expected to show the highest growth with a CAGR of 16.40% during the upcoming years. There is a rise in the development of epigenetic diagnostics and therapies. They are also being used in the development of personalized treatments, enhancing the clinical trials.

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Developments in the Epigenetics Market

In September 2025, for antiphospholipid syndrome ("APS") the VolitionRx Limited, which is a multi-national epigenetics company, and Werfen's Immunoassay Technology Center, which is a leader in specialized diagnostics, signed a Research License and Exclusive Commercial Option Rights Agreement.
In August 2025, the first age-reversing epigenetic serum, that is Cellular Epigenetics Rejuvenating Serum, was launched by Beiersdorf, which is a parent company of Nivea.
In June 2025, the AB Chopra Epigenetics, which is a revolutionary longevity platform combining epigenetic science, consciousness-based healing, and artificial intelligence to redefine the future of well-being, was launched by the collaboration between the co-founder of Augustinus Bader skincare and biotech company Charles Rosier, and Deepak Chopra, MD.
In December 2024, the world’s first comprehensive epigenetic map, providing invaluable insights into the impact of lifestyle choices and environmental factors on disease progression, without altering the DNA sequence itself, will be developed by the collaboration between Genomics England, NHS England, UK Biobank, and Oxford Nanopore Technologies.

Epigenetics Market Key Players

Element Biosciences, Inc.
Roche Diagnostics
Dovetail Genomics LLC.
Thermo Fisher Scientific, Inc.
PacBio
Illumina, Inc.
Merck KGaA
GeneTex, Inc.
Abcam Limited
Eisai Co., Ltd.
Diagenode s.a.
Domainex
Novartis AG
Epigenica
Epizyme, Inc.
BioVision Inc.
Bio-Rad Laboratories, Inc.
Active Motif, Inc.
AsisChem Inc.

Browse More Insights of Towards Healthcare:

The global immune repertoire sequencing market was valued at US$ 337.43 million in 2024 and is expected to reach US$ 370 million in 2025, ultimately hitting US$ 842.44 million by 2034, growing at a CAGR of 9.64% over the forecast period.

The global high content screening market stood at USD 1.52 billion in 2024 and is projected to rise to USD 1.63 billion in 2025, reaching approximately USD 3.12 billion by 2034, at a CAGR of 7.54% between 2025 and 2034.

The global CRISPR market started at US$ 2.94 billion in 2024 and is anticipated to grow to US$ 3.27 billion by 2025, surpassing US$ 8.58 billion by 2034, with a steady CAGR of 11.24%.

The perfusion systems market was estimated at US$ 1.15 billion in 2023 and is forecast to expand to US$ 1.94 billion by 2034, registering a CAGR of 4.85% from 2024 to 2034.

The global plasmid DNA manufacturing market reached US$ 1.85 billion in 2023 and is expected to soar to US$ 12.27 billion by 2034, growing at a robust CAGR of 18.77% from 2024 to 2034.

The in vivo CAR-T platform market is advancing rapidly worldwide, with revenues projected to accumulate hundreds of millions between 2025 and 2034.

The global spatial proteomics market was valued at US$ 87.54 million in 2024 and is predicted to grow to US$ 100.78 million in 2025, eventually reaching US$ 358.12 million by 2034, expanding at a CAGR of 15.14% between 2025 and 2034.

The global synthetic tissue engineering market stood at US$ 1.51 billion in 2024, is expected to rise to US$ 1.72 billion in 2025, and reach US$ 5.61 billion by 2034, growing at a CAGR of 14.14% over the forecast period.

The global GMP-grade cytokines market was valued at USD 2.54 billion in 2024, is projected to climb to USD 2.79 billion in 2025, and reach USD 6.48 billion by 2034, expanding at a CAGR of 9.84%.

The global ENT devices market was calculated at US$ 19.59 billion in 2024, is expected to increase to US$ 20.88 billion in 2025, and is projected to hit US$ 36.71 billion by 2034, growing at a CAGR of 6.54%.

Segments Covered in The Report

By Product

Reagents
Kits
- Chip Sequencing Kit
- Whole Genomic Amplification Kit
- Bisulfite Conversion Kit
- RNA sequencing Kit
- Others
Instruments
Enzymes
Services

By Technology

DNA Methylation
Histone Methylation
Histone Acetylation
Large non-coding RNA
MicroRNA Modification
Chromatin Structures

By Application

Oncology
- Solid Tumors
- Liquid Tumors
Non-oncology Oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others

By End-use

Academic Research
Clinical Research
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other Users

By Region

North America

U.S.
Canada

Asia Pacific

China
Japan
India
South Korea
Thailand

Europe

Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway

Latin America

Brazil Mexico
Argentina

Middle East and Africa (MEA)

South Africa
UAE
Saudi Arabia
Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5164

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.